Generic atorvastatin and health care costs

New England Journal of Medicine

Volumn 366, Issue 3, 2012, Pages 201-204

  Jackevicius, Cynthia A ^a,b,c,d   Chou, Mindy M ^e   Ross, Joseph S ^f,g   Shah, Nilay D ^h   Krumholz, Harlan M ^f,g  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e INDIAN HEALTH SERVICE   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g YALE NEW HAVEN HOSPITAL   (United States)

^h MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

BIOEQUIVALENCE; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; DRUG MEGADOSE; DRUG QUALITY; DRUG SUBSTITUTION; DRUG USE; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; PATENT; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY; UNITED STATES;

EID: 84856158984     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1113112     Document Type: Article

References (5)

1. 2010 U.S. spending and prescription information. IMS Health. April 7, 2011 (http:// www.imshealth.com/portal/site/imshealth/ menuitem. a46c6d4df3db4b3d88f611019418c 22a/?vgnextoid=ed2e5a6b5895f210VgnVCM1 00000ed152ca2RCRD&cpsextcurrchannel=1).
2. Orange Book: approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: Food and Drug Administration, February 15, 2011 (http://www.accessdata .fda.gov/scripts/cder/ob/docs/patexclnew.cfm ?Appl-No=020702&Product-No=004& table1=OB-Rx).
3. Stiles S. Tie announced in SATURN rosuvastatin- atorvastatin face-off (http://www .theheart.org/article/1273751.do).
4. Peterson M. Pfizer may get generic Lipitor delay. September 1, 2011 (http://www .bloomberg.com/news/2011-09-01/pfizer-may-get-generic-lipitor-delay. html).
5. Kale MS, Bishop TF, Federman AD, Keyhani S. "Top 5" lists top $5 billion. Arch Intern Med 2011;171:1856-8.